Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 14/20 | 0.46 |
| ▸ | NQO1 | P15559 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10141791 | 0.79 | IDO1 (0.55) | IDO1NQO1KDM4EMEN1ALDH1A1 | |
| SCHEMBL18791102 | 0.75 | IDO1 (0.56) | IDO1NQO1KDM4EMEN1ALDH1A1 | |
| SCHEMBL104948 | 0.71 | IDO1 (0.45) | IDO1NQO1KDM4EMEN1ALDH1A1 | |
| SCHEMBL104949 | 0.71 | IDO1 (0.45) | IDO1NQO1KDM4EMEN1ALDH1A1 | |
| SCHEMBL171092 | 0.71 | IDO1 (0.45) | IDO1NQO1KDM4EMEN1ALDH1A1 | |
| SCHEMBL104950 | 0.71 | IDO1 (0.45) | IDO1NQO1KDM4EMEN1ALDH1A1 | |
| SCHEMBL30076102 | 0.70 | IDO1 (0.56) | IDO1NQO1KDM4EMEN1ALDH1A1 | |
| SCHEMBL20811248 | 0.69 | IDO1 (0.59) | IDO1NQO1KDM4EMEN1ALDH1A1 | |
| SCHEMBL14439350 | 0.69 | IDO1 (0.43) | IDO1NQO1KDM4EMEN1ALDH1A1 | |
| SCHEMBL14439344 | 0.69 | IDO1 (0.43) | IDO1NQO1KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1545507-A4 | ACTIVATED CHECKPOINT THERAPY AND METHODS OF USE THEREOF | ARQULE INC (US) | 2009-04-22 | — | — | EP | claimed |
| EP-1545507-A2 | ACTIVATED CHECKPOINT THERAPY AND METHODS OF USE THEREOF | Arqule, Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040209942-A1 | Activated checkpoint therapy and methods of use thereof | BETH ISRAEL DEACONESS MEDICAL CENTER | 2004-10-21 | — | — | US | claimed |
| WO-2004007531-A2 | ACTIVATED CHECKPOINT THERAPY AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2004-01-22 | — | — | WO | claimed |
| US-20120021432-A1 | Phosphorylated NF45 Biomarkers, Antibodies And Methods Of Using Same | ARQULE, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| EP-1545507-A4 | ACTIVATED CHECKPOINT THERAPY AND METHODS OF USE THEREOF | ARQULE INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2033638-A2 | Beta-lapachone for the treatment of pancreatic cancer | Arqule, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-2033640-A2 | Beta-lapachone for the treatment of lung cancer | Arqule, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-2033639-A2 | Beta-lapachone for the treatment of colon cancer | Arqule, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-1729760-A2 | USE OF BETA-LAPACHONE FOR THE TREATMENT OF LUNG CANCER | Arqule, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1727536-A1 | BETA-LAPACHONE AND S-PHASE DRUG COMBINATIONS FOR CANCER TREATMENT | Arqule, Inc. (US) | 2006-12-06 | — | — | EP | disclosed |
| EP-1722777-A2 | USE OF BETA-LAPACHONE FOR THE TREATMENT OF PANCREATIC CANCER | Arqule, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050192361-A1 | Method of treatment of colon cancer | ARQULE, INC. | 2005-09-01 | — | — | US | disclosed |
| US-20050187288-A1 | Beta-lapachone and methods of treating cancer | ARQULE, INC. | 2005-08-25 | — | — | US | disclosed |
| EP-1545507-A2 | ACTIVATED CHECKPOINT THERAPY AND METHODS OF USE THEREOF | Arqule, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050054018-A1 | Activated checkpoint therapy and methods of use thereof | LI CHIANG J (US) | 2005-03-10 | — | — | US | disclosed |
| US-20040253730-A1 | Activated checkpoint therapy and methods of use thereof | LI CHIANG J (US) | 2004-12-16 | — | — | US | disclosed |
| US-20040253216-A1 | Activated checkpoint therapy and methods of use thereof | LI CHIANG J (US) | 2004-12-16 | — | — | US | disclosed |
| US-20040209942-A1 | Activated checkpoint therapy and methods of use thereof | BETH ISRAEL DEACONESS MEDICAL CENTER | 2004-10-21 | — | — | US | disclosed |
| WO-2004007531-A2 | ACTIVATED CHECKPOINT THERAPY AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040253730-A1 | Activated checkpoint therapy and methods of use thereof | TP53, CHEK1, CHEK2 | IDO1 2294/4885NQO1 1671/4885KDM4E 2490/4885 |
| US-20050192361-A1 | Method of treatment of colon cancer | MKI67, APC, TUBB1 | IDO1 1591/4885NQO1 52/4885KDM4E 2882/4885 |
| US-20040209942-A1 | Activated checkpoint therapy and methods of use thereof | TP53, CHEK1, CHEK2 | IDO1 2294/4885NQO1 1671/4885KDM4E 2490/4885 |
| US-20120021432-A1 | Phosphorylated NF45 Biomarkers, Antibodies And Methods Of Using Same | NFKB1, NFKBIA, CDC45 | IDO1 4513/4885NQO1 2892/4885KDM4E 2598/4885 |
| US-20040253216-A1 | Activated checkpoint therapy and methods of use thereof | TP53, CHEK1, CHEK2 | IDO1 2294/4885NQO1 1671/4885KDM4E 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.